Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY – PLUS

Project description

Haematological malignancies data analysis to improve access to new therapies

Haematological malignancies (HM) are a heterogeneous group of diseases with complicated diagnostics and extremely complex treatments. The goal of the EU-funded HARMONY PLUS project is to collect, store and analyse the current HM information to speed up and support the decision-making process for patients’ access to new therapies. The project uses the capabilities of the HARMONY Big Data platform to match the unmet needs by expanding the scope to incorporate myeloproliferative neoplasms including chronic myeloid leukaemia, polycythaemia vera, essential thrombocythaemia and myelofibrosis as well as lymphoproliferative disorders including Hodgkin’s lymphoma, Waldenström macroglobulinaemia and all rare HMs not covered by the previous HARMONY project.

Objective

Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be easily diagnosed nor treated. Nowadays most treatments are extremely complex, and advances in patient diagnosis and therapies slow due to the low number of patients per centre. Thus, there is a need to harmonise, store, and analyse the current HM information to speed-up and support the decision-making process for patients’ access to new therapies.

HARMONY PLUS takes advantage of the capabilities of the HARMONY Big Data platform to match these unmet needs by expanding its scope to incorporate myeloproliferative neoplasms, including chronic myeloid leukemia, polycythaemia vera, essential thrombocythaemia, and myelofibrosis; and lymphoproliferative disorders, including Hodgkin’s lymphoma, Waldenström macroglobulinemia and all the other rare HMs not covered by HARMONY Project. In parallel, HARMONY PLUS will continue to refine and define the Core Outcome Sets (COS), especially for these new HMs to ensure the use by researchers of useful common outcomes relevant to all stakeholders. As previously accomplished in HARMONY, HARMONY PLUS is committed to pursue the maximum ethical and legal requirements, particularly to ensure patient’s right to privacy.

Data-driven research within Europe will be enhanced by converting the current HARMONY platform into an Integrated Services Platform to serve as a valuable tool to support clinical trial design and use of available data as a control arm. This platform, combined with a HaemoDatabank repository with information about HMs patient biological samples across Europe, will facilitate a more efficient research and clinical trial design, and consequently will promote collaborations with recognised databases outside Europe. From the regulatory point of view, HARMONY PLUS will be a valuable technology tool during the evaluation of new treatments and drugs by also considering the patients’ needs.

Coordinator

FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
Net EU contribution
€ 1 606 368,02
Address
PARQUE SANTA CLARA
42002 Soria
Spain

See on map

Region
Centro (ES) Castilla y León Soria
Activity type
Research Organisations
Links
Total cost
€ 2 474 594,27

Participants (42)